ResearcherUniversity of EssexNo recent work listed
Andrea Mohr
Matched on ORCID iD 0000-0002-4295-0341; OpenAlex author ID A5079931511.
Their work
Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.
- Pancreatic cancer papers
- 3 (first author 2, last author 0)
- Pancreatic cancer trials
- 0
- Pancreatic cancer grants
- 0
- Collaborators
- 2
2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper
Papers 3
- Fas-threshold signalling in MSCs promotes pancreatic cancer progression and metastasis. First author DOI 10.1016/j.canlet.2021.06.017↗
- TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. First author DOI 10.1186/s12885-015-1508-2↗
- DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. Co-author DOI 10.4161/15384047.2014.972183↗
Closest collaborators
The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Ralf Michael Zwacka · 3 shared papers, 2014–2021
- Paper Fas-threshold signalling in MSCs promotes pancreatic cancer progression and metastasis. DOI 10.1016/j.canlet.2021.06.017↗
- Paper TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. DOI 10.1186/s12885-015-1508-2↗
- Paper DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. DOI 10.4161/15384047.2014.972183↗
- Rui Yu · 2 shared papers, 2014–2015
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.